Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 31, 2026Current Drug Therapy

Design, Synthesis, and Cytotoxic Evaluation of 1,3,4-Thiadiazolyl- Benzamides as Potent BRAF Inhibitors: Integrating In Vitro and In Silico Approaches

View Full Paper
Ask AI
Bookmark
Share

Authors

PIPugazh IndhumathyRGR. Gandhimathi

Discussion

Loading...

Member takes

Overview

Novel thiadiazolyl-benzamides demonstrate potent cytotoxicity in melanoma cells, suggesting new therapeutic options.

Key Points

  • The aim was to design and evaluate new thiadiazolyl-benzamide derivatives as BRAF inhibitors to combat melanoma.
  • Synthesis of compounds via a two-step protocol
  • Characterization using spectroscopic techniques
  • Molecular docking studies with BRAF kinase crystal structure
  • In silico ADMET analyses for pharmacokinetics
  • In vitro cytotoxicity testing using the MTT assay on M-14 and B16-F1 cell lines.
  • Docking studies showed several derivatives had strong binding affinities to BRAF.
  • Compound IA25 had the highest docking score of -9.7 kcal/mol, forming two key hydrogen bonds.
  • IC₅₀ values for active compounds ranged from 33.93 to 40.62 nM, indicating strong anti-proliferative effects.
  • ADMET analysis showed favorable bioavailability, stability, and low toxicity for the compounds.

Cite This Study

Indhumathy et al. (2026) studied this question.

synapsesocial.com/papers/69cb6541e6a8c024954b95bfhttps://doi.org/10.2174/0115748855431795260109102847
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design, Synthesis, Molecular Docking, <scp>ADME</scp>‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential <scp>BRAF<sup>V600E</sup></scp><sup>/<scp>WT</scp></sup> Inhibitors2025 · 1 citations
  2. 2Structure‐Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulation for the Discovery of Novel BRAF(V600E) Inhibitors in Melanoma Cancer2026
  3. 3Design and Synthesis of Pyrimidino[4,5‐ <i>d</i> ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors2026
  4. 4Novel 2-oxo-tetrahydropyrimidine derivatives as BRAFV600E inhibitors targeting melanoma: Design, synthesis and anticancer activity2024
  5. 5Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone2016 · 11 citations